Keywords: aeterna, completes, enrolment, ph, ii, nsclc, trial

AEterna completes enrolment in Ph II NSCLC trial

Article | 19 November 2007

Canadian drugmaker AEterna Zentaris has completed patient recruitment in its European multicenter Phase II non-small cell lung cancer trial of ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Drugs

Nystatin

Go to drug listing